Novopharm acyclovir
Executive Summary
FDA determines that Novopharm's acyclovir 200 mg tablets were not withdrawn due to reasons of safety or efficacy, following April citizen petition submitted by TorPharm. Novopharm decided not to market its generic after approval of the ANDA on April 22, 1997